iCAD Stock - Analyst coverage and AI breast imaging focus

iCAD stock draws interest around its AI-powered breast imaging and cancer detection business, while coverage from smaller research houses outlines expectations for growth and funding needs. A look at operations, strategy and valuation context for the Nasdaq-listed medtech.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 14:13 UTC. Details in the imprint.

iCAD (US45071L1098) develops AI-powered imaging and therapy solutions for cancer detection and treatment. As a smaller Nasdaq-listed medtech name, the company sits at the intersection of healthcare IT and diagnostics, drawing specialist investor attention.

Operational footprint and strategy

iCAD positions itself as a provider of AI-enabled decision support tools and targeted radiation therapy for oncology, with a core focus on breast cancer screening and treatment workflows across hospitals and imaging centers.

The company’s investor materials highlight a two-pillar model: breast AI for imaging clinics and oncology therapy solutions intended to optimize radiation delivery and minimize exposure to healthy tissue.

Analyst coverage and expectations

Coverage of iCAD stock is concentrated among smaller brokerages and healthcare-specialist research firms, which typically focus on revenue growth potential from AI software as a service and the company’s path to sustainable profitability.

Consensus data from financial portals tend to list only a handful of active ratings, underlining that the stock remains a niche name compared with large-cap medtech peers.

The product behind the stock

iCAD’s portfolio centers on its ProFound AI solution for digital breast tomosynthesis, which uses deep learning algorithms to help radiologists detect breast cancer earlier and with improved workflow efficiency in screening programs.

Where the stock trades today

The shares of iCAD with ISIN US45071L1098 trade on Nasdaq in US dollars; the latest available quote data from public market sources indicate a low mid-cap valuation level for the company.

Key facts on iCAD stock

• Company: iCAD Inc.
• ISIN: US45071L1098
• WKN: 939746
• Ticker: ICAD
• Venue: Nasdaq
• Sector / Industry: Health Care / Health Care Technology

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.